Lanair^®

Lanair^® contains the active substance montelukast.

Lanair^® is a leukotriene receptor antagonist that inhibits substances called leukotrienes. Leukotrienes cause narrowing and swelling of the airways of the lungs. By inhibiting leukotrienes, Lanair^® relieves asthma symptoms and helps control asthma.

Lanair^® chewable tablets are indicated as an asthma adjunct in patients between 2 and 5 years of age (4 mg-KT) and between 6 and 14 years of age (5 mg-KT) with mild to moderate persistent asthma that is not adequately treated with inhaled corticosteroids and cannot be adequately controlled with the use of ‘as needed’ short-acting beta-agonists.

Lanair^® may also be a treatment alternative to low-dose inhaled corticosteroids in patients aged 2-5 years (4 mg-KT) or 6-14 years (5 mg-KT) with mild persistent asthma who have not had recent severe asthma attacks treatable with oral corticosteroids and who have been shown to be unable to use inhaled corticosteroids.

In addition, Lanair^® may be used in children 2 years of age and older (4 mg-KT) or 6 years of age and older (5 mg-KT) for the prevention of asthma whose predominant component is exercise-induced bronchoconstriction.

Lanair^® film-coated tablets are indicated as an asthma adjunct in patients 15 years of age and older with mild to moderate persistent asthma that is not adequately treated with inhaled corticosteroids and cannot be adequately controlled with the use of ‘as needed’ short-acting beta-agonists.

In those asthma patients for whom Lanair^® is indicated for asthma, Lanair^® may also relieve the symptoms of seasonal allergic rhinitis.

In addition, Lanair^® can be used in patients 15 years of age and older to prevent asthma, the predominant component of which is exercise-induced bronchoconstriction.